Company

Onconic Therapeutics Inc.

Onconic Therapeutics develops drug candidates for cancer and gastrointestinal diseases.

About

Seoul-based Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, conducts research and development of drugs for cancer and gastrointestinal diseases. Its candidates include OCN-201, an anti-cancer drug, and Zastaprazan (OCN-101), a potassium-competitive acid blocker for gastric acid-related diseases. In December 2022, it raised KRW 26 billion in Series B funding from AJU IB Investment, K2 Investment Partners, KDB Bank and SL Investment to support clinical trials and development approvals.

2Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in